Meryl Waldman, Ninet Sinaii, Edgar V. Lerma, Anila Abraham Kurien, Kenar D. Jhaveri, Nupur N. Uppal, Rimda Wanchoo, Rupali Avasare, Jonathan E. Zuckerman, Adrian Liew, Alexander J. Gallan, Ashraf El-Meanawy, Yoram Yagil, Larissa Lebedev, Krishoban Baskaran, Eswari Vilayur, Adrienne Cohen, Nethmi Weerasinghe, Ioannis Petrakis, Kostas Stylianou, Hariklia Gakiopoulou, Alexander J. Hamilton, Naomi Edney, Rachel Millner, Smaragdi Marinaki, Joshua L. Rein, John Paul Killen, Jose Manuel Rodríguez Chagolla, Claude Bassil, Ramon Lopez del Valle, Jordan Evans, Anatoly Urisman, Mona Zawaideh, Pravir V. Baxi, Roger Rodby, Mahesha Vankalakunti, Juan M. Mejia Vilet, Silvia E. Ramirez Andrade, Mal P. Homan, Enzo Vásquez Jiménez, Natasha Perinpanayagam, Juan Carlos Q. Velez, Muner M.B. Mohamed, Khalid M.G. Mohammed, Arjun Sekar, Laura Ollila, Abraham W. Aron, Kevin Javier Arellano Arteaga, Mahmud Islam, Esperanza Moral Berrio, Omar Maoujoud, Rebecca Ruf Morales, Regan Seipp, Carl E. Schulze, Robert H. Yenchek, Irina Vancea, Muhammad Muneeb, Lilian Howard, and Tiffany N. Caza
ORIGINAL INVESTIGATIONCOVID-19 Vaccination and new onset glomerular disease: Results from the IRocGN2 International registryWaldman, Meryl1,a; Sinaii, Ninet2; Lerma, Edgar V.3; Kurien, Anila Abraham4; Jhaveri, Kenar D.5; Uppal, Nupur N.5; Wanchoo, Rimda5; Avasare, Rupali6; Jonathan E, Zuckerman7; Liew, Adrian8; Gallan, Alexander J9; El-Meanawy, Ashraf10; Yagil, Yoram11; Lebedev, Larissa11; Baskaran, Krishoban12,13; Vilayur, Eswari12; Seung, Adrienne Wai12; Weerasinghe, Nethmi12; Petrakis, Ioannis14; Stylianou, Kostas15; Gakiopoulou, Hariklia16; Hamilton, Alexander J17; Edney, Naomi18; Millner, Rachel19; Marinaki, Smaragdi20; Rein, Joshua L21; Killen, John Paul22,23; Rodríguez Chagolla, Jose Manuel24; Bassil, Claude25; Lopez del Valle, Ramon26; Evans, Jordan27; Urisman, Anatoly28; Zawaideh, Mona29; Baxi, Pravir V.30; Rodby, Roger30; Vankalakunti, Mahesha31; Mejia Vilet, Juan M.32; Ramirez Andrade, Silvia E.33; Homan, Mal34; Jiménez, Enzo Vásquez35; Perinpanayagam, Natasha36; Carlos Q Velez, Juan37,38; Mohamed, Muner M.B.37,38; Mohammed, Khalid M.G39; Sekar, Arjun40; Ollila, Laura41; Aron, Abraham W42; Arellano Arteaga, Kevin Javier43; Islam, Mahmud44; Berrio, Esperanza Moral45; Maoujoud, Omar46; Morales, Rebecca Ruf47; Seipp, Regan48; Schulze, Carl E49; Yenchek, Robert H50; Vancea, Irina51; Muneeb, Muhammad52; Howard, Lilian1; Caza, Tiffany N53Author InformationKidney360 ():10.34067/KID.0006832022, December 16, 2022. | DOI: 10.34067/KID.0006832022OPENPAPMetricsAbstractBackground: Cases of de novo glomerular disease with various renal histologies have been reported after vaccination against SARS-CoV-2. Causality has not been established and the long-term outcomes are not known. To better characterize the glomerular diseases and clinical course/outcomes, we created the International Registry of COVID-19 vaccination and Glomerulonephritis (IRocGN2) to study in aggregate de novo glomerulonephritis cases suspected after COVID-19 vaccine exposure.:Methods: A RedCap survey was used for anonymized data collection. Detailed information on vaccination type and timing and glomerular disease histology were recorded in the registry. We collected serial information on laboratory values (before and after vaccination and during follow-up), treatments, and kidney-related outcomes.Results: Ninety-eight glomerular disease cases were entered into the registry over eleven months from 44 centers throughout the world. Median follow-up was 89 days after diagnosis. IgA nephropathy (IgAN) and minimal change disease (MCD) were the most the common kidney diseases reported. Recovery of kidney function and remission of proteinuria was more likely in IgAN and MCD at 4-6 months than with pauci immune glomerulonephritis /vasculitis and membranous nephropathy.Conclusions: Development of glomerular disease after vaccination against SARS-CoV-2 may be a very rare adverse event. Temporal association is present for IgAN and MCD, but causality is not firmly established. Kidney outcomes for IgAN and MCD are favorable. No changes in vaccination risk-benefit assessment is recommended based on these findings.